Royal Australasian College

The Inner Circle acknowledges Antony Jackson Arumairaj, MD as a Top Pinnacle Physician

Retrieved on: 
화요일, 4월 2, 2024
College, Research, American Medical Association, Royal Australasian College, Internal medicine, Critical Care Medicine (journal), Patient, Publishing, Emergency medicine, MD, American College of Physicians, Mentorship, Royal college, American Thoracic Society, Society, Bachelor, American College, Stanley Medical College, Internship, Multimedia, Health, Inner circle, Teaching, Nursing

JERSEY CITY, N.J., April 2, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Antony Jackson Arumairaj, MD is acknowledged as a Top Pinnacle Physician for his contributions as a Distinguished Internal Medicine Specialist.

Key Points: 
  • JERSEY CITY, N.J., April 2, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Antony Jackson Arumairaj, MD is acknowledged as a Top Pinnacle Physician for his contributions as a Distinguished Internal Medicine Specialist.
  • In this capacity, he not only provides exceptional patient care but also plays a pivotal role in teaching and mentoring medical students.
  • His dedication to the well-being of his patients and commitment to medical education make him a valuable asset to the healthcare community.
  • He aims to complete his Pulmonary Critical Care fellowship and become an Attending Physician at a university hospital.

Find Therapeutics Announces Appointment of Dr. Anthony Johnson to its Board of Directors

Retrieved on: 
월요일, 3월 4, 2024
University, OrbiMed, Pharmacology, AstraZeneca, MD, University of Cambridge, Royal Australasian College, Bristol Myers Squibb, BMS, Homerton College, Cambridge, Therapy, Find, Royal college, Internal medicine, GSK plc, MBBS, Physician, Discovery Medicine, Pharmaceutical industry

"On behalf of the Board of Directors, I am delighted to welcome Tony to the team," said Philippe Douville, President and CEO of Find Therapeutics.

Key Points: 
  • "On behalf of the Board of Directors, I am delighted to welcome Tony to the team," said Philippe Douville, President and CEO of Find Therapeutics.
  • He currently serves as President and CEO of Domain Therapeutics, Chairman of the Board for Outrun Therapeutics and Board Director for Nanosyrinx.
  • Dr. Johnson was previously President and CEO of Goldfinch Bio and, prior to that, Head of Early Clinical Development.
  • Find Therapeutics also announces that Pascal Neuville, Ph.D., has stepped down from the board as a Non-Executive Director effective March 3, 2024.

Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company

Retrieved on: 
월요일, 1월 8, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, OrbiMed, Multimedia, AstraZeneca, Gq alpha subunit, Research, Physician, Fellow, Therapy, Cancer, GSK, PNT, University, Royal Australasian College, GPCR, Growth, Patient, Bristol Myers Squibb, Management

View the full release here: https://www.businesswire.com/news/home/20240108886645/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240108886645/en/
    Michael’s appointment as Chairman follows Laurence Rulleau and Youssef Bennani, who held the role for 9 years.
  • An industry expert with international experience leading biopharmaceutical companies, Michael is also currently the President and Chief Executive Officer of RENOGENYX.
  • As the new President and CEO, based in Boston, Tony succeeds Pascal Neuville who founded and successfully led the Company for the past 15 years.
  • Their respective expertise and track record in pioneering and leading biopharmaceutical companies will be invaluable to the Company and will support our reach and global focus.

Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023

Retrieved on: 
화요일, 5월 9, 2023
Infection, University, Necrosis, Patient satisfaction, Cone Health Women's Hospital, ISO, Clinical trial, Cancer, Quality of life, HBI, CMO, Princess Alexandra Hospital, Elizabeth Wagele, Senior lecturer, Patient, Royal Australasian College of Surgeons, Royal Brisbane and Women's Hospital, RACS, Hospital, Medtech, Royal Australasian College, Polycaprolactone, Medical device, Silk, Medical imaging, Dentistry, Breast

The results were presented at the 91st Annual Scientific Congress 2023 of the Royal Australasian College of Surgeons (RACS) .

Key Points: 
  • The results were presented at the 91st Annual Scientific Congress 2023 of the Royal Australasian College of Surgeons (RACS) .
  • Michael Wagels, Principal Investigator of the first clinical trial evaluating BellaSeno's implant with autologous fat grafting for pectus excavatum camouflage, reported 3-year data from the first in-human case.
  • Not only was the implant safe and well tolerated, but histologic studies demonstrated tissue growth and vascularization within the implant scaffold.
  • Wagels also presented animal data from large 450 ccm scaffolds showing that tissue was fully regenerated in this large volume without the development of necrosis.

Experts Share Insights on Evolving Global Vaccine Landscape Including mRNA Trends

Retrieved on: 
금요일, 3월 3, 2023
Research, European, Mater Group, NEXT Woman of the Year awards, Royal college, Australasian, University of the Philippines Manila, Consultant, Senior, Editor-in-chief, Toxicology, IND, Protein, University, Royal Australasian College, Infection, COVID-19, ChromeOS, Marie Cassidy, Associate, Acquisition, Tropical medicine, Principal, Vaccine, Clinical trial, IVI, Drug development, Pharmacist, International Vaccine Institute, Licensure, SOP, Drug Development and Industrial Pharmacy, Medical microbiology, SK, Babaji, Pharmaceutical industry, Fine chemical, Pharmacology, Physician, Medicine

Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.

Key Points: 
  • Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
  • Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.
  • Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • The acquisition is part of Novotech’s global expansion program in Europe and the US.

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
수요일, 2월 15, 2023
University of the Philippines Manila, Toxicology, International Vaccine Institute, Royal college, Marie Cassidy, Acquisition, Clinical trial, Editor-in-chief, Vaccine, Infection, SOP, Protein, SK, University, Drug Development and Industrial Pharmacy, European, NEXT Woman of the Year awards, Royal Australasian College, IVI, Babaji, Pharmacist, Licensure, Research, Mater Group, Medical microbiology, Associate, COVID-19, Principal, ChromeOS, Drug development, Tropical medicine, Senior, Australasian, Consultant, IND, Pharmaceutical industry, Fine chemical, Physician, Medicine, Pharmacology

Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.

Key Points: 
  • Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
  • Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.
  • Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • The acquisition is part of Novotech’s global expansion program in Europe and the US.

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
수요일, 2월 15, 2023
University of the Philippines Manila, Toxicology, International Vaccine Institute, Royal college, Marie Cassidy, Acquisition, Clinical trial, Editor-in-chief, Bharat Biotech, Vaccine, Infection, SOP, Protein, SK, University, Drug Development and Industrial Pharmacy, European, Global Jurist of the Year Award, Royal Australasian College, IVI, Babaji, Pharmacist, Licensure, Research, Mater Group, Medical microbiology, Associate, COVID-19, Principal, ChromeOS, AU, Drug development, Tropical medicine, Senior, Australasian, Consultant, IND, Pharmaceutical industry, Fine chemical, Physician, Medicine, Pharmacology

SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.

Key Points: 
  • SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.
  • https://novotech-cro.com/whitepapers/vaccines-asia-pacific-clinical-tria...
    The webinar, Keeping pace with the evolving global landscape in vaccine development, will hear from a panel of life science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space including:
    - The COVID-19 impact on drug development and the regulatory landscape.
  • - Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage.
  • - Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

Retrieved on: 
수요일, 9월 14, 2022
Osteopathy, Arnold, Royal Australasian College, American College, Efficiency, MD, Galidesivir, BioCryst Pharmaceuticals, University, Royal college, Hematology, Michigan State University College of Osteopathic Medicine, Industry, Otorhinolaryngology, Therapy, Yellow fever, Patient, Goal, American College of Physicians, Marburg virus disease, MB BS, Science, Osteopathic medicine in the United States, MB, RESEARCH, Neurology, Research, GLOBE, Oncology, PARK, University college, Biogen, Disease, Pharmaceutical industry, Medical device, Genzyme, Amgen, Physician

RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the companys significant pipeline of development candidates.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the companys significant pipeline of development candidates.
  • Dr. Ryan Arnold has been appointed as the companys new chief medical officer.
  • Dr. Arnold joins Dr. Sheridan and Dr. Helen Thackray, the companys chief research and development officer, as physicians on the companys leadership team.
  • Dr. Sheridan joined BioCryst from Amgen in July 2008 as chief medical officer.

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

Retrieved on: 
목요일, 7월 7, 2022
Patient, Carmine, Achondroplasia, CEO, Medarex, B cell, Novartis, Pulmonology, Physiology, BMS, Amoxicillin/clavulanic acid, Bay, BioMarin Pharmaceutical, Nobel Prize, Senior advisor, Formoterol, SA, BMN, Nobel Prize in Physiology or Medicine, CMO, MBA, Non-executive director, GlaxoSmithKline, SVP, Bristol Myers Squibb, Haemophilia, EVP, Physician, Royal Australasian College, Royal college, Sangamo Therapeutics, VP, Board, Multiple myeloma, Drug development, Batten disease, Lymphatic system, Pharmaceutical industry, Pegvaliase, Medicine, Omalizumab, Phenylketonuria

Bryce Carmine, HaemaLogiX's Chairman and CEO commented: "Geoff's impressive, globally recognised background in drug development, and in particular, in antibody development, makes him a valuable contribution to the HaemaLogiX board.

Key Points: 
  • Bryce Carmine, HaemaLogiX's Chairman and CEO commented: "Geoff's impressive, globally recognised background in drug development, and in particular, in antibody development, makes him a valuable contribution to the HaemaLogiX board.
  • Importantly, during his time at Medarex, Geoff oversaw the preclinical and clinical development of KappaMab, our multiple myeloma drug candidate.
  • He brings outstanding industry knowledge and a highly translatable skillset to our Board mix.
  • Dr. Nichol brings nearly 30 years' experience in drug development.

Pulnovo Medical Announces Dr. Krishna Sudhir Joins Scientific Advisory Board

Retrieved on: 
수요일, 6월 15, 2022
American College of Cardiology, Industry, FDA, Hypertensive emergency, Global, Heart, Society, Technology, Intervention, Royal Australasian College, Royal college, United States Air Force Scientific Advisory Board, Monash University, American College, Director, Medical Affairs Bureau, Research, San Francisco, VaxGen, MD, University, Stanford University, Pharmacyclics, University of California, San Francisco, SAB, Digital image processing, CFDA, Patient, Board, Madras Medical College, Center, Multimedia, OTM, Johnson & Johnson, Degenerative disease, Medical device, Medicine, Physician

SHANGHAI, June 15, 2022 /PRNewswire/ --Pulnovo Medical Limited, a globally recognized OTM innovation platform, recently announced that Dr. Krishna Sudhir has officially joined the Pulnovo Medical Scientific Advisory Board.

Key Points: 
  • SHANGHAI, June 15, 2022 /PRNewswire/ --Pulnovo Medical Limited, a globally recognized OTM innovation platform, recently announced that Dr. Krishna Sudhir has officially joined the Pulnovo Medical Scientific Advisory Board.
  • Dr. Krishna Sudhir will provide scientific guidance and take an important part in the innovation and internationalization of Pulnovo Medical's technology platforms and R&D portfolio.
  • Regarding the board position with Pulnovo Medical, Dr. Sudhir said, "I am proud to be joining as a member of the SAB to contribute to the technology development, commercialization, and research innovation of Pulnovo Medical.
  • Pulnovo Medical, said, "On behalf of Pulnovo Medical and the Board of Directors, I welcome Dr. Krishna Sudhir in joining our Scientific Advisory Board.